10-Q: Dror Ortho-Design Reports Q1 2025 Results, Cites Ongoing Development and Need for Additional Capital

Dror Ortho-Design, Inc. announced its Q1 2025 financial results, highlighting ongoing research and development of its orthodontic alignment platform and the necessity for additional funding to sustain operations.

Summary

• Dror Ortho-Design, Inc. reported a net loss of $576,123 for the three months ended March 31, 2025, compared to a net loss of $1,308,463 for the same period in 2024.
• Research and development expenses decreased by 36% to $239,604, primarily due to reduced software development activities.
• General and administrative expenses decreased by 19% to $313,629, mainly due to lower professional fees.
• Share-based compensation expenses significantly decreased by 96% to $23,193, due to the completion of the vesting period for most options in 2024.
• The company's cash balance as of March 31, 2025, was $349,851, after using $499,593 in operating activities during the quarter.
• The company received $300,000 in bridge loans from existing investors during the quarter, with interest and repayment terms yet to be finalized.
• Dror Ortho-Design is in the development stage and has not generated any revenues.
• The company is dependent on external sources for financing its operations and needs to raise additional capital to fund operating losses and grow its operations.
• Management expresses substantial doubt about the company's ability to continue as a going concern for the next twelve months without additional funding.
• The company intends to spend approximately $2.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's ongoing losses, lack of revenue, dependence on external funding, and management's doubt about the company's ability to continue as a going concern. However, there are some positive aspects, such as the decrease in net loss compared to the previous year and the decrease in operating expenses.

Positives

• The net loss decreased from $1,308,463 in Q1 2024 to $576,123 in Q1 2025.
• Research and development expenses decreased by 36% year-over-year.
• General and administrative expenses decreased by 19% year-over-year.
• Share-based compensation expenses decreased significantly by 96% year-over-year.

Negatives

• The company reported a net loss of $576,123 for Q1 2025.
• The company has not generated any revenues.
• The company's cash balance as of March 31, 2025, was $349,851.
• Management has substantial doubt about the company's ability to continue as a going concern without additional funding.

Risks

• The company is in the development stage and has no operating history in the manufacturing and distribution of orthodontic medical devices or platforms for consumer use.
• The company's products and technologies may not be accepted by the intended commercial consumers.
• The company expects continued operating losses and cannot be certain of future profitability.
• The company will face competition from large internationally established aligner companies.
• The company may not receive the necessary authorizations to market its Platform or any future new products.
• The company's Common Stock is not listed on any stock exchange and there is a limited market for shares of its Common Stock.
• The company needs to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as its products do not reach commercial profitability.
• There are no assurances that the Company would be able to raise additional capital on terms favorable to it.
• If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail, or cease operations.

Future Outlook

The company intends to spend approximately $2.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection. The company will need to raise additional capital to fund operating losses and grow its operations. Management has substantial doubt about the company's ability to continue as a going concern for the next twelve months without additional funding.

Management Comments

• Management has substantial doubt about the Company's ability to continue as a going concern.

Industry Context

The company is attempting to disrupt the aligner market with a new technology. The company faces competition from large internationally established aligner companies whose products have been widely accepted.

Comparison to Industry Standards

• The report does not provide enough information to compare the company's results to industry standards.
• The company is in the development stage and has not generated any revenues, making it difficult to compare to established companies in the aligner market such as Align Technology (Invisalign) or SmileDirectClub.
• The company's success will depend on its ability to obtain regulatory clearance for its Platform and achieve market acceptance of its products.

Legal Proceedings

• From time to time, the Company may be involved in litigation that arises through the normal course of business.
• As of the date of this filing, we are not a party to any material litigation nor are we aware of any such threatened or pending litigation.
• There are no proceedings in which any of our directors, officers, affiliates or any registered or beneficial stockholders is an adverse party or has a material interest adverse to our interest.

Related Party Transactions

• On June 1, 2022, the Company entered into a consulting agreement with Yehuda Englander, a director of the Company.
• On February 7, 2024, the Company amended the Consulting Agreement which provides that Mr. Englanders monthly cash fee in respect of the services provided under the Consulting Agreement will equal $2,500 and in addition to the monthly fee, Mr. Englander is entitled to expense reimbursements in an amount not to exceed $500.
• On February 7, 2024, the Company entered into a consulting agreement with Chaim Ravad, a director of the Company.
• On August 8, 2023, the Company entered into a consulting agreement with Oriole, an entity owned by Yaacov Bodner, an owner of 5% or more of the Companys outstanding shares of Common Stock.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional equity capital.
• Employees face uncertainty due to the company's going concern status.
• The company's ability to develop and commercialize its Platform will impact customers seeking orthodontic treatment.
• The company's financial condition may affect its ability to meet obligations to suppliers and creditors.

Next Steps

• The company intends to spend approximately $2.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection.
• The company is currently in discussions with the lenders to determine the terms of the loan agreements.
• The company will need to raise additional capital to fund operating losses and grow its operations.

Key Dates

Keywords

orthodontic alignment platform, research and development, financial results, going concern, capital raising, net loss, Dror Ortho-Design, aligner market, FDA clearance